Correction: Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling (PLoS ONE (2013) 8, 10 (e78881) DOI:10.1371/journal.pone.0078881);Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Nguyen, Holly M ^a   Ruppender, Nazanin ^a   Zhang, Xiaotun ^a   Brown, Lisha G ^a   Gross, Ted S ^b   Morrissey, Colm ^a   Gulati, Roman ^c   Vessella, Robert L ^a   Schimmoller, Frauke ^d   Aftab, Dana T ^d   Corey, Eva ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

^d EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CABOZANTINIB; PROTEIN P MET; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANDROGEN SENSITIVE PROSTATE CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BONE MASS; BONE METASTASIS; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; CANCER INHIBITION; CANCER STAGING; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERANCE; ENZYME ACTIVITY; HORMONE SENSITIVITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SUBCUTANEOUS TISSUE TUMOR; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR VOLUME; WEIGHT REDUCTION;

ANDROGENS; ANILIDES; ANIMALS; BODY WEIGHT; BONE REMODELING; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; MICE; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886383394     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106797     Document Type: Erratum

References (44)

1. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, et al. (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10: 2298-2308. doi:10.1158/1535-7163.MCT-11-0264. PubMed: 21926191.
2. You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, et al. (2011) VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 71: 4758-4768. doi:10.1158/0008-5472.CAN-10-2527. PubMed: 21613405.
3. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, et al. (2013) Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol 31: 412-419. doi:10.1200/JCO.2012.45.0494. PubMed: 23169517.
4. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, et al. (2012) Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2: 270-287. doi:10.1158/2159-8290.CD-11-0240 PubMed: 22585997.
5. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, et al. (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29: 2660-2666. doi:10.1200/JCO.2010.32.4145. PubMed: 21606412.
6. Ceolin L, Siqueira DR, Ferreira CV, Romitti M, Maia SC, et al. (2012) Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness. Eur J Endocrinol 166: 847-854. doi:10.1530/EJE-11-1060. PubMed: 22345297.
7. Ceolin L, Siqueira DR, Romitti M, Ferreira CV, Maia AL, (2012) Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET Polymorphisms. Int J Mol Sci 13: 221-239. PubMed: 22312249.
8. Knudsen BS, Edlund M, (2004) Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 91: 31-67. doi:10.1016/S0065-230X(04)91002-0. PubMed: 15327888.
9. Strohmeyer D, Strauss F, Rössing C, Roberts C, Kaufmann O, et al. (2004) Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res 24: 1797-1804. PubMed: 15274358.
10. Nakashiro K, Hayashi Y, Oyasu R, (2003) Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Oncol Rep 10: 1149-1153. PubMed: 12883672.
11. Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, et al. (2010) Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 9: 9. doi:10.1186/1476-4598-9-9. PubMed: 20085644.
12. Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, et al. (2006) Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer 4: 269-274. doi:10.3816/CGC.2006.n.006. PubMed: 16729910.
13. Verras M, Lee J, Xue H, Li TH, Wang Y, et al. (2007) The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 67: 967-975. doi:10.1158/0008-5472.CAN-06-3552. PubMed: 17283128.
14. Maeda A, Nakashiro K, Hara S, Sasaki T, Miwa Y, et al. (2006) Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells. Biochem Biophys Res Commun 347: 1158-1165. doi:10.1016/j.bbrc.2006.07.040. PubMed: 16870139.
15. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, et al. (2011) The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs 20: 1677-1684. doi:10.1517/13543784.2011.631523. PubMed: 22035268.
16. Tu WH, Zhu C, Clark C, Christensen JG, Sun Z, (2010) Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer 10: 556. doi:10.1186/1471-2407-10-556. PubMed: 20946682.
17. Kim SJ, Johnson M, Koterba K, Herynk MH, Uehara H, et al. (2003) Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res 9: 5161-5170. PubMed: 14613995.
18. Dai Y, Siemann DW, (2010) BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther 9: 1554-1561. doi:10.1158/1535-7163.MCT-10-0359. PubMed: 20515943.
19. Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, et al. (2013) Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone. Clin Cancer Res 19: 215-224. doi:10.1158/1078-0432.CCR-12-2605. PubMed: 23136195.
20. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, et al. (2011) Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29: 1271-1279. doi:10.1200/JCO.2010.31.0367. PubMed: 21383285.
21. Tomić TT, Gustavsson H, Wang W, Jennbacken K, Welén K, et al. (2012) Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2. Prostate 72: 705-712. doi:10.1002/pros.21472. PubMed: 21809353.
22. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, et al. (1999) Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54: 523-527. doi:10.1016/S0090-4295(99)00167-3. PubMed: 10475365.
23. Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, et al. (2001) Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 61: 2533-2536. PubMed: 11289126.
24. Casanovas O, Hicklin DJ, Bergers G, Hanahan D, (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309. doi:10.1016/j.ccr.2005.09.005. PubMed: 16226705.
25. Small AC, Oh WK, (2012) Bevacizumab treatment of prostate cancer. Expert Opin Biol Ther 12: 1241-1249. doi:10.1517/14712598.2012.704015. PubMed: 22775507.
26. Kitajima Y, Ide T, Ohtsuka T, Miyazaki K, (2008) Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci 99: 1341-1347. doi:10.1111/j.1349-7006.2008.00828.x. PubMed: 18422749.
27. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, et al. (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361. doi:10.1016/S1535-6108(03)00085-0. PubMed: 12726861.
28. Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG, (2012) HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett 320: 48-55. doi:10.1016/j.canlet.2012.01.026. PubMed: 22269210.
29. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, et al. (2010) HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 70: 10090-10100. doi:10.1158/0008-5472.CAN-10-0489. PubMed: 20952508.
30. Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E, (2010) Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia 12: 192-205. PubMed: 20126477.
31. Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, et al. (2009) A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol 17: 57-67. doi:10.1097/PAI.0b013e3181816ae2. PubMed: 18815565.
32. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, et al. (1996) Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 2: 1039-1048. PubMed: 9816265.
33. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, et al. (2002) Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 52: 20-33. doi:10.1002/pros.10091. PubMed: 11992617.
34. Koreckij TD, Trauger RJ, Montgomery RB, Pitts TE, Coleman I, et al. (2009) HE3235 inhibits growth of castration-resistant prostate cancer. Neoplasia 11: 1216-1225. PubMed: 19881957.
35. Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, et al. (2006) Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia 8: 862-878. doi:10.1593/neo.06328. PubMed: 17032503.
36. Emami KH, Brown LG, Pitts TE, Sun X, Vessella RL, et al. (2009) Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate 69: 1481-1492. doi:10.1002/pros.20998. PubMed: 19514049.
37. Corey E, Vessella RL, (2006) Xenograft models of human prostate cancer. In: Chung LWK, Isaacs WB, Simons JW, eds. Prostate Cancer: Biology, Genetics and the New Therapeutics. Tottowa, NJ: Humana Press. pp. pp. 3-33.
38. Nurmio M, Joki H, Kallio J, Määttä JA, Väänänen HK, et al. (2011) Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats. Toxicol Appl Pharmacol 254: 267-279. doi:10.1016/j.taap.2011.04.019. PubMed: 21586300.
39. Gschwind A, Fischer OM, Ullrich A, (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4: 361-370. doi:10.1038/nrc1360. PubMed: 15122207.
40. Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, et al. (2010) GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12: 116-127. PubMed: 20126470.
41. Dawson DM, Lawrence EG, MacLennan GT, Amini SB, Kung HJ, et al. (1998) Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst 90: 519-523. doi:10.1093/jnci/90.7.519. PubMed: 9539247.
42. Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, et al. (2008) C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia 10: 996-1003. PubMed: 18714401.
43. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA, (2011) Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med 17: 657-664. doi:10.1007/s00894-010-0756-y. PubMed: 21365123.
44. Pfitzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, et al. (2003) Characterization of C4-2 prostate cancer bone metastases and their response to castration. J Bone Miner Res 18: 1882-1888. doi:10.1359/jbmr.2003.18.10.1882. PubMed: 14584899.